Stock listing

NASDAQ:VIVS VivoSim Labs, Inc. Stock

Home listing (NASDAQ) of VivoSim Labs, Inc.

Follow VivoSim Labs, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VIVS

$0.171 USD +0.014 (+8.8%)

Close on Oct 20, 2026

Past 3 months -82.7% · daily closes, Jul 6, 2026 – Oct 20, 2026, adjusted for splits

Day range: $0.159 – $0.185 USDOct 20, 2026
Volume: 644,453 sharesOct 20, 2026
Market cap: $2.79M USDAt the close on Oct 20, 2026 · price × 16.27M shares outstanding

Prices by listing

Listing	Last	Change	Volume	Open	High	Low	Previous close	Price from
NASDAQ:VIVS · Home	$0.171 USD	+0.014 (+8.8%)	644,453	$0.160	$0.185	$0.159	$0.158	Close on Oct 20, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 20, 2026 · NASDAQ:VIVS · USD, adjusted for splits

Day	Close	Change	%	Open	High	Low	Volume
Tue, Oct 20	$0.171	+0.014	+8.8%	$0.160	$0.185	$0.159	644,453
Mon, Oct 19	$0.158	+0.001	+0.4%	$0.159	$0.165	$0.156	338,694
Fri, Oct 16	$0.157	-0.014	-8.2%	$0.163	$0.169	$0.153	818,269
Thu, Oct 15	$0.171	+0.010	+6.3%	$0.157	$0.190	$0.150	3,365,851
Wed, Oct 14	$0.161	-0.013	-7.6%	$0.169	$0.171	$0.160	361,047
Tue, Oct 13	$0.174	+0.000	+0.1%	$0.179	$0.179	$0.172	180,875
Mon, Oct 12	$0.174	-0.006	-3.4%	$0.179	$0.182	$0.169	1,102,971
Fri, Oct 9	$0.180	+0.003	+1.6%	$0.178	$0.184	$0.168	334,512
Thu, Oct 8	$0.177	-0.013	-6.7%	$0.194	$0.194	$0.175	872,724
Wed, Oct 7	$0.190	-0.010	-5.0%	$0.200	$0.210	$0.190	881,200
Tue, Oct 6	$0.200	-0.010	-4.8%	$0.210	$0.210	$0.200	374,900
Mon, Oct 5	$0.210	+0.010	+5.0%	$0.200	$0.210	$0.190	444,300
Fri, Oct 2	$0.200	-0.010	-4.8%	$0.210	$0.210	$0.190	804,500
Thu, Oct 1	$0.210	0.000	0.0%	$0.210	$0.220	$0.210	185,300
Wed, Sep 30	$0.210	+0.010	+5.0%	$0.200	$0.220	$0.200	558,100
Tue, Sep 29	$0.200	-0.020	-9.1%	$0.230	$0.230	$0.200	647,800
Mon, Sep 28	$0.220	0.000	0.0%	$0.230	$0.230	$0.220	423,900
Fri, Sep 25	$0.220	-0.010	-4.3%	$0.230	$0.230	$0.220	253,000
Thu, Sep 24	$0.230	0.000	0.0%	$0.230	$0.230	$0.220	559,000
Wed, Sep 23	$0.230	-0.010	-4.2%	$0.240	$0.240	$0.220	615,400
Tue, Sep 22	$0.240	-0.010	-4.0%	$0.250	$0.260	$0.230	1,242,600
Mon, Sep 21	$0.250	+0.020	+8.7%	$0.230	$0.260	$0.220	1,451,300
Fri, Sep 18	$0.230	-0.030	-11.5%	$0.260	$0.260	$0.220	1,568,400
Thu, Sep 17	$0.260	0.000	0.0%	$0.270	$0.270	$0.260	595,100
Wed, Sep 16	$0.260	-0.010	-3.7%	$0.270	$0.270	$0.250	6,387,800
Tue, Sep 15	$0.270	-0.010	-3.6%	$0.280	$0.280	$0.270	304,700
Mon, Sep 14	$0.280	0.000	0.0%	$0.290	$0.290	$0.270	389,100
Fri, Sep 11	$0.280	-0.020	-6.7%	$0.300	$0.300	$0.280	419,900
Thu, Sep 10	$0.300	+0.020	+7.1%	$0.280	$0.300	$0.270	1,401,200
Wed, Sep 9	$0.280	0.000	0.0%	$0.280	$0.290	$0.270	398,200
Tue, Sep 8	$0.280	0.000	0.0%	$0.280	$0.290	$0.270	696,900
Fri, Sep 4	$0.280	0.000	0.0%	$0.280	$0.280	$0.280	267,900
Thu, Sep 3	$0.280	0.000	0.0%	$0.280	$0.280	$0.270	606,300
Wed, Sep 2	$0.280	0.000	0.0%	$0.280	$0.280	$0.270	386,600
Tue, Sep 1	$0.280	-0.010	-3.4%	$0.300	$0.300	$0.270	366,400
Mon, Aug 31	$0.290	0.000	0.0%	$0.290	$0.290	$0.280	358,800
Fri, Aug 28	$0.290	0.000	0.0%	$0.290	$0.300	$0.290	230,800
Thu, Aug 27	$0.290	0.000	0.0%	$0.290	$0.300	$0.280	333,000
Wed, Aug 26	$0.290	-0.002	-0.5%	$0.290	$0.300	$0.280	283,100
Tue, Aug 25	$0.292	0.000	-0.1%	$0.287	$0.300	$0.281	647,948
Mon, Aug 24	$0.292	+0.002	+0.7%	$0.284	$0.304	$0.276	969,780
Fri, Aug 21	$0.290	+0.010	+3.6%	$0.280	$0.290	$0.270	715,800
Thu, Aug 20	$0.280	0.000	0.0%	$0.280	$0.280	$0.270	803,200
Wed, Aug 19	$0.280	0.000	0.0%	$0.280	$0.290	$0.270	1,766,800
Tue, Aug 18	$0.280	-0.040	-12.5%	$0.310	$0.320	$0.260	2,062,600
Mon, Aug 17	$0.320	0.000	0.0%	$0.320	$0.330	$0.310	1,113,300
Fri, Aug 14	$0.320	-0.010	-3.0%	$0.330	$0.330	$0.320	1,509,800
Thu, Aug 13	$0.330	0.000	0.0%	$0.330	$0.340	$0.320	1,473,600
Wed, Aug 12	$0.330	-0.020	-5.7%	$0.350	$0.350	$0.330	2,248,800
Tue, Aug 11	$0.350	-0.010	-2.8%	$0.360	$0.370	$0.350	3,279,600
Mon, Aug 10	$0.360	-0.110	-23.4%	$0.410	$0.420	$0.350	6,772,200
Fri, Aug 7	$0.470	+0.140	+42.4%	$0.320	$0.580	$0.310	97,915,600
Thu, Aug 6	$0.330	-0.030	-8.3%	$0.390	$0.390	$0.310	3,033,900
Wed, Aug 5	$0.360	-0.010	-2.7%	$0.370	$0.380	$0.350	1,149,100
Tue, Aug 4	$0.370	+0.040	+12.1%	$0.330	$0.380	$0.320	2,934,600
Mon, Aug 3	$0.330	-0.010	-2.9%	$0.340	$0.350	$0.320	1,649,200
Fri, Jul 31	$0.340	-0.050	-12.8%	$0.420	$0.420	$0.320	5,883,800
Thu, Jul 30	$0.390	+0.050	+14.7%	$0.340	$0.420	$0.310	5,642,700
Wed, Jul 29	$0.340	-0.040	-10.5%	$0.370	$0.370	$0.330	1,089,400
Tue, Jul 28	$0.380	-0.010	-2.6%	$0.380	$0.390	$0.360	592,800
Mon, Jul 27	$0.390	-0.030	-7.1%	$0.390	$0.400	$0.360	1,376,700
Fri, Jul 24	$0.420	-0.030	-6.7%	$0.450	$0.450	$0.410	1,509,000
Thu, Jul 23	$0.450	-0.010	-2.2%	$0.450	$0.460	$0.430	995,500
Wed, Jul 22	$0.460	+0.010	+2.2%	$0.430	$0.480	$0.430	2,666,300
Tue, Jul 21	$0.450	-0.050	-10.0%	$0.560	$0.570	$0.440	66,211,800
Mon, Jul 20	$0.500	-0.080	-13.8%	$0.560	$0.580	$0.490	2,225,000

Ticker: NASDAQ:VIVS
Asset type: Stock
Sector: Health care
Industry: Diagnostics & research services
Exchange: NASDAQ
Currency: USD

What changed lately

Latest news release · Oct 21, 2026
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Latest deck · 2026
Investor Presentation (2026)
Investor deck · 22 slides

Latest news

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Oct 21, 2026

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Oct 7, 2026

Closed $0.19 (-5.0%) on Oct 7, 2026

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Sep 16, 2026

Closed $0.26 (-3.7%) on Sep 16, 2026

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Sep 1, 2026

Closed $0.28 (-3.4%) on Sep 1, 2026

VivoSim Provides Financial and Listing Compliance Update

Aug 6, 2026

Closed $0.33 (-8.3%) on Aug 6, 2026

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Jul 21, 2026

Closed $0.45 (-10.0%) on Jul 21, 2026

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Jul 16, 2026

Closed $0.61 (-28.2%) on Jul 16, 2026

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

Jul 15, 2026

Closed $0.85 (+2.4%) on Jul 15, 2026

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

Jun 29, 2026

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

Apr 28, 2026

All VivoSim Labs, Inc. news

Financings

Private placement of pre-funded warrants and common warrants
Aug 6, 2026
Closed: US$4M raised · US$0.85 a share · Warrants at US$0.85 for 60 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Working capital and general corporate purposes
Announced Jul 16, 2026 · Closed Aug 6, 2026

Read by 6ix AI from the company's releases

Decks

Investor Presentation (2026)
Investor deck · 22 slides · 2026

VivoSim Labs, Inc. on 6ix

Sector: Health care
Industry: Diagnostics & research services
News releases: 19 in the last 12 months · 69 in all · newest Oct 21, 2026 · oldest 2019
Decks: 1 deck · latest 2026

Where VivoSim Labs, Inc. is listed

Listing	Exchange	Country	Currency
NASDAQ:VIVS · Home listing · This page	NASDAQ	United States	USD
Munich:4OR	Munich	Germany	EUR
LSE:0R02	LSE	United Kingdom	USD
gettex:4OR	gettex	Germany	EUR
BOATS:VIVS	BOATS	United States	USD
Frankfurt:4OR	Frankfurt	Germany	EUR
LS Exchange:A41083	LS Exchange	Germany	EUR
Lang & Schwarz:A41083	Lang & Schwarz	Germany	EUR
Stuttgart:4OR	Stuttgart	Germany	EUR

NASDAQ:VIVS VivoSim Labs, Inc. Stock

Prices by listing

Daily closes

What changed lately

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Investor Presentation (2026)

Latest news

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

VivoSim Provides Financial and Listing Compliance Update

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

Financings

Private placement of pre-funded warrants and common warrants

Decks

Investor Presentation (2026)

VivoSim Labs, Inc. on 6ix

Where VivoSim Labs, Inc. is listed